Targetting deregulated signalling pathways in high-grade serous ovarian cancer: Defining therapeutic response and mechanisms of resistance
Grant number: 1043884 | Funding period: 2013 - 2015
Ovarian cancer is the major cause of death from gynaecological cancer. Most patients present with advanced disease and die of their cancer. This proposal aims to use new research detailing the common genetic changes in tumour samples and our extensive panel of ovarian cancer cell lines to identify new treatment options for specific types of ovarian cancer. We expect this will result in clinical trials of therapies selected based on the characteristics of an individual patient’s disease.
Related publications (8)
Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population
Nadine Hein, Donald P Cameron, Katherine M Hannan, Nhu-Y N Nguyen, Chun Yew Fong, Jirawas Sornkom, Meaghan Wall, Megan Pavy, Carleen Cullinane, Jeannine Diesch, Jennifer R Devlin, Amee J George, Elaine Sanij, Jaclyn Quin, Gretchen Poortinga, Inge Verbrugge, Adele Baker, Denis Drygin, Simon J Harrison, James D Rozario
Despite the development of novel drugs, the prospects for many patients with acute myeloid leukemia (AML) remain dismal. This stud..
Cell cycle and growth stimuli regulate different steps of RNA polymerase I transcription
Sandy S Hung, Analia Lesmana, Abigail Peck, Rachel Lee, Elly Tchoubrieva, Katherine M Hannan, Jane Lin, Karen E Sheppard, Katarzyna Jastrzebski, Leonie M Quinn, Lawrence I Rothblum, Richard B Pearson, Ross D Hannan, Elaine Sanij
Transcription of the ribosomal RNA genes (rDNA) by RNA polymerase I (Pol I) is a major control step for ribosome synthesis and is ..
The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer
Shunfei Yan, Daniel Frank, Jinbae Son, Katherine M Hannan, Ross D Hannan, Keefe T Chan, Richard B Pearson, Elaine Sanij
Overall survival for patients with ovarian cancer (OC) has shown little improvement for decades meaning new therapeutic options ar..
Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling
Jaclyn Quin, Keefe T Chan, Jennifer R Devlin, Donald P Cameron, Jeannine Diesch, Carleen Cullinane, Jessica Ahern, Amit Khot, Nadine Hein, Amee J George, Katherine M Hannan, Gretchen Poortinga, Karen E Sheppard, Kum Kum Khanna, Ricky W Johnstone, Denis Drygin, Grant A McArthur, Richard B Pearson, Elaine Sanij, Ross D Hannan
RNA polymerase I (Pol I)-mediated transcription of the ribosomal RNA genes (rDNA) is confined to the nucleolus and is a rate-limit..
Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma
Jennifer R Devlin, Katherine M Hannan, Nadine Hein, Carleen Cullinane, Eric Kusnadi, Pui Yee Ng, Amee J George, Jake Shortt, Megan J Bywater, Gretchen Poortinga, Elaine Sanij, Jian Kang, Denis Drygin, Sean O'Brien, Ricky W Johnstone, Grant A McArthur, Ross D Hannan, Richard B Pearson
UNLABELLED: Ribosome biogenesis and protein synthesis are dysregulated in many cancers, with those driven by the proto-oncogene c-..
Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition
Sally J Davis, Karen E Sheppard, Michael S Anglesio, Joshy George, Nadia Traficante, Sian Fereday, Maria P Intermaggio, Usha Menon, Aleksandra Gentry-Maharaj, Jan Lubinski, Jacek Gronwald, Celeste Leigh Pearce, Malcolm C Pike, Anna Wu, Stefan Kommoss, Jacobus Pfisterer, Andreas du Bois, Felix Hilpert, Susan J Ramus, David DL Bowtell
Identification of genomic alterations defining ovarian carcinoma subtypes may aid the stratification of patients to receive target..
Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors
Karen E Sheppard, Carleen Cullinane, Katherine M Hannan, Meaghan Wall, Joanna Chan, Frances Barber, Jung Foo, Donald Cameron, Amelia Neilsen, Pui Ng, Jason Ellul, Margarete Kleinschmidt, Kathryn M Kinross, David D Bowtell, James G Christensen, Rodney J Hicks, Ricky W Johnstone, Grant A McArthur, Ross D Hannan, Wayne A Phillips
BACKGROUND: Ovarian cancer is the major cause of death from gynaecological malignancy with a 5year survival of only ∼30% due to re..
AKT signalling is required for ribosomal RNA synthesis and progression of E mu-Myc B-cell lymphoma in vivo
Jennifer R Devlin, Katherine M Hannan, Pui Y Ng, Megan J Bywater, Jake Shortt, Carleen Cullinane, Grant A McArthur, Ricky W Johnstone, Ross D Hannan, Richard B Pearson
The dysregulation of PI3K/AKT/mTORC1 signalling and/or hyperactivation of MYC are observed in a high proportion of human cancers, ..